Deutsche Bank Aktiengesellschaft Upgrades Gilead Sciences (NASDAQ:GILD) to Buy
Gilead Sciences (NASDAQ:GILD – Get Free Report) was upgraded by research analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The firm presently has a $120.00 price objective on the biopharmaceutical company’s stock, up from their previous […]
Gilead Sciences (NASDAQ:GILD – Get Free Report) was upgraded by research analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The firm presently has a $120.00 price objective on the biopharmaceutical company’s stock, up from their previous […]
